Spexis AG

About Spexis AG

Spexis is focused on delivering continuous hope for rare disease and cancer patients through innovative medicines and breakthrough platforms.

Products & Services

Inhaled Murepavadin:A product likely aimed at treating specific conditions, detailed on the company website.

Balixafortide:A therapeutic product with potential applications in rare diseases or cancer, detailed on the company website.

Lonodelestat:An external product collaboration, possibly for specific medical treatments, linked to Santhera’s website.

Breakthrough Platforms:Innovative platforms for drug development or therapeutic solutions, detailed on the company website.

Specialties

Rare Disease Treatments Cancer Therapies Innovative Medicine Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 2500000 MR: - FA: 2.5 million FAN: 2500000	D: 2023-08-14 FD: 2023-08-14	2 investors
2	RT: Debt T: - FT: Debt	A: 4500000 MR: - FA: 4.5 million FAN: 4500000	D: 2023-04-18 FD: 2023-04-18	1 investors

Debt Latest

2023-08-14

$2.5M

2 investors (Pro only)

Debt 2023-04-18

$4.5M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jeffrey D. Wager

Chief Executive Officer

J

Juergen Froehlich

Chief Medical Officer

D

Dennis A. Ausiello

Vice Chairman

K

Kuno Sommer

Non-Executive Board Member

D

Dan Hartman

Director, Integrated Development for the Gates Foundation

R

Robert Clarke

Board Member

View 4 more team members with Pro

Unlock Full Team Directory

Recent News

Spexis AG Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised